Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cymbalta Clear all
Completed Not applicable Interventional Results available

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NCT03534063
View directory record Official record
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

Duloxetine Versus Placebo for Fibromyalgia

NCT00489073
View directory record Official record
Conditions
Fibromyalgia
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2007 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 31, 2026, 1:46 AM EDT
Recruiting Not applicable Interventional

Procedural Framing and Epidural Steroid Injection Outcomes

NCT07498140
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
Behavioral manipulation of ESI expectations, No behavioral manipulation of ESI expectations, No behavioral manipulation of pharmacotherapy expectations
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 1:46 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE)

NCT07649291
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Depression
Interventions
Exercise, Duloxetine, Placebo, PT referral
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization

NCT03548454
View directory record Official record
Conditions
Chronic Pain
Interventions
Duloxetine, Desipramine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in Chronic Low Back Pain

NCT00408876
View directory record Official record
Conditions
Back Pain Without Radiation
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fort Myers, Florida • Orlando, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 31, 2026, 1:46 AM EDT
Recruiting Phase 4 Interventional

Duloxetine for LBP

NCT05851976
View directory record Official record
Conditions
Back Pain, Low
Interventions
Naproxen, Duloxetine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 31, 2026, 1:46 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 31, 2026, 1:46 AM EDT
Withdrawn Phase 4 Interventional

Duloxetine Tibial Plateau

NCT04639011
View directory record Official record
Conditions
Tibial Plateau Fracture, Pain, Postoperative
Interventions
Duloxetine, Placebo, Standard of care (SOC) for tibial plateau surgery
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

NCT01035073
View directory record Official record
Conditions
Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence

NCT00190853
View directory record Official record
Conditions
Urinary Stress Incontinence
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • West Palm Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 31, 2026, 1:46 AM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache

NCT00443352
View directory record Official record
Conditions
Migraine
Interventions
duloxetine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Not applicable Interventional Results available

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

NCT01028352
View directory record Official record
Conditions
Breast Cancer
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 31, 2026, 1:46 AM EDT
Withdrawn Phase 2 Interventional

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

NCT02857244
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Duloxetine, Donepezil, Modafinil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Effect of Combined Morphine and Duloxetine on Chronic Pain

NCT03249558
View directory record Official record
Conditions
Chronic Low Back Pain, Chronic Neck Pain
Interventions
Morphine, Duloxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Gastric Bypass on Blood Levels of Duloxetine

NCT00989157
View directory record Official record
Conditions
Bariatric Surgery
Interventions
Duloxetine
Drug
Lead sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 2 Interventional

Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence

NCT00190567
View directory record Official record
Conditions
Urinary Stress Incontinence
Interventions
duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 2 Interventional

Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)

NCT03315533
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Duloxetine 30 milligrams (MG), Duloxetine 60 milligrams (MG), Placebo Oral Tablet
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 31, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

NCT00105989
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Newport Beach, California • Sherman Oaks, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 31, 2026, 1:46 AM EDT
Withdrawn Not applicable Interventional

OASIS: Osteoarthritis Sensitivity Integration Study

NCT01377038
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
Phenotype assessment
Other
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 31, 2026, 1:46 AM EDT